Laromustine

Drug Profile

Laromustine

Alternative Names: 101M; Cloretazine; Onrigin; VNP 4010M; VNP40101M

Latest Information Update: 02 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University
  • Developer Vion Pharmaceuticals
  • Class Antineoplastics; Hydrazines; Small molecules; Sulfonamides
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Glioma; Myelodysplastic syndromes
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 27 Feb 2010 Vion receives an FDA response relating to the SPA for the phase II/III trial in Acute myeloid leukaemia
  • 13 Jan 2010 Vion files a Special Protocol Assessment for a phase II//III trial of laromustine in combination with low-dose Ara-C in elderly patients with newly diagnosed Acute myeloid leukaemia in USA
  • 15 Dec 2009 Vion receives complete response letter from the FDA for laromustine in Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top